See today's BioWorld
To read the full story, subscribe or sign in.

Phio flies on complete responses in phase I skin cancer trial

Jan. 13, 2025
By Karen Carey
Shares of Phio Pharmaceuticals Corp. soared 291% Jan. 13 on news that two patients with cutaneous squamous cell carcinoma had a complete response following treatment with the company’s Intasyl siRNA gene silencing candidate PH-762.
BioWorld Clinical Cancer Dermatologic Gene therapy U.S.